Sanofi-aventis stärker sin organisation
Sanofi-aventis befinner sig i en expansiv fas med förberedelser inför lansering av ny produkt och många spännande studier i pipeline. Detta resulterar i en omfattande rekrytering.
Ämnen: Vetenskap, teknik
-
-
GENERAL MEETING OF SHAREHOLDERS
The Combined General Meeting of Shareholders of sanofi-aventis was held May 31, 2006.
-
NEW ELOXATIN® AND TAXOTERE® DATA IN SEVERAL TUMOR TYPESTO BE PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
- 430 abstracts from studies involving Taxotere® or Eloxatin® accepted at the meetings scientific sessions -
-
ADJUVANTED FORMULATION OF SANOFI PASTEUR H5N1 PANDEMIC INFLUENZA VACCINE CANDIDATE DEMONSTRATES SIGNIFICANT IMMUNE RESPONSE
Lyon, France May 11, 2006 A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well-tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram (µg) dosage generated the most substantive immune response (
-
Sanofi-aventis: Results First quarter of 2006
First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis1 52.8% growth in adjusted EPS1 and 19.8% excluding selected items3
-
Läkemedlet Acomplia godkänns i Europa
Läkemedlet Acomplia (rimonabant) har idag fått så kallad positive opinion från den europeiska läkemedelsmyndigheten EMEA och förväntas därmed bli godkänt i Sverige och övriga Europa. Formellt beslut tas av EU-kommissionen senare i sommar. Sanofi-aventis räknar med att Acomplia kommer att finnas tillgänglig på den svenska marknaden i slutet av det här året.
-
TRANSFER OF ALL JAPANESE RIMONABANT RIGHTS TO SANOFI-AVENTIS
As part of its strategy to strengthen its presence in Japan, sanofi-aventis announced today that it has agreed with Astellas Pharma Inc. to accelerate the transfer of all rights to rimonabant in Japan from a joint-venture company held by the two groups to sanofi-aventis.
-
LANMET STUDY SHOWS LANTUS® PLUS METFORMIN TO BE EFFECTIVE AND WELL-TOLERATED IN INITIATING INSULIN THERAPY IN TYPE 2 DIABETES
Achieving good glycemic control with less hypoglycemia and less weight gain
-
TAXOTERE® RECEIVES POSITIVE OPINION
TAXOTERE® RECEIVES POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE RECOMMENDING APPROVAL IN THE EUROPEAN UNION FOR METASTATIC STOMACH CANCER
-
TAXOTERE® RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER
TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
-
New therapy significantly reduces risk of repeat heart attack and death
Brigham and Womens Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy For Heart Attacks - New therapy significantly reduces risk of repeat heart attack and death
-
FIRST LARGE SCALE INTERNATIONAL PRIMARY CARE STUDY CONFIRMS A HIGH WAIST CIRCUMFERENCE IS INDEPENDENTLY ASSOCIATED WITH CARDIOVASCULAR DISEASE
Results from the IDEA Study Highlight the Rising Worldwide Pandemic of Abdominal Obesity
-
Varannan svensk vill minska sin midja
Om svensken själv får välja är det den tjocka magen som ska bort. 51 procent av svenskarna vill ha smalare midja. En majoritet anger omsorg om hälsan som skäl, inte utseende. Det visar en färsk undersökning från Temo.
-
STUDY ANALYZES GENE THERAPY FOR PATIENTS AT HIGH RISK FOR AMPUTATION
NV1FGF Injection Reduces and Delays Risks of Amputation in Patients with Limb Ischemia
-
CHARISMA: NEW STUDY FURTHERS UNDERSTANDING OF THE ROLE OF DUAL ANTIPLATELET THERAPY IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS
Results from the CHARISMA trial showed that the combination of the antiplatelet agents clopidogrel and aspirin did not demonstrate a statistically significant reduction in the risk of heart attack, stroke or cardiovascular death compared to placebo and aspirin in a broad population of patients with either established atherothrombotic disease or multiple risk factors for atherothrombotic events.
-
Apidra ® A New Rapid-Acting Insulin Analog is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
New prandial insulin with the OptiClik® delivery system can work with longer-acting insulins, such as basal insulin Lantus®, providing a complementary approach to glucose control
-
SANOFI PASTEUR DELIVERS MORE H5N1 VACCINE FOR U.S. GOVERNMENT PANDEMIC INITIATIVES
Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.
-
Svenska Cardiologföreningen och sanofi-aventis stödjer forskning rörande prevention av hjärtkärlsjukdomar med utgångspunkt från kända kardiovaskulära och metabola riskfaktorer.
Svenska Cardiologföreningen och sanofi-aventis utlyser ett stipendium om 150 000 kronor inom området kardiometabol risk.
-
MY CHILD MATTERS: LAUNCH OF A MOBILISATION CAMPAIGN AGAINST CHILDHOOD CANCER IN EMERGING COUNTRIES
The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
-
PLAVIX® APPROVED IN JAPAN
Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.
Visa mer
Loading...